BI Asset Management Fondsmaeglerselskab A S Raises Stake in DaVita Inc. (NYSE:DVA)

BI Asset Management Fondsmaeglerselskab A S increased its stake in DaVita Inc. (NYSE:DVA - Free Report) by 153.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,873 shares of the company's stock after acquiring an additional 79,742 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned 0.16% of DaVita worth $19,722,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of DVA. Invesco Ltd. lifted its position in DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after acquiring an additional 275,284 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Amundi boosted its position in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the last quarter. Epoch Investment Partners Inc. bought a new stake in DaVita during the fourth quarter worth $55,100,000. Finally, KBC Group NV raised its position in DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company's stock valued at $47,281,000 after buying an additional 2,636 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

Analyst Ratings Changes

DVA has been the topic of a number of recent analyst reports. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Thursday, April 10th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Barclays lifted their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $166.33.

DaVita Stock Performance

DaVita stock traded up $0.71 during trading on Thursday, hitting $139.64. The stock had a trading volume of 648,254 shares, compared to its average volume of 838,478. The stock's 50 day moving average is $147.16 and its two-hundred day moving average is $155.53. DaVita Inc. has a 1 year low of $130.96 and a 1 year high of $179.60. The stock has a market cap of $11.17 billion, a price-to-earnings ratio of 13.00, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.